Influence of concurrent capecitabine based chemoradiotherapy with bevacizumab on the survival rate, late toxicity and health-related quality of life in locally advanced rectal cancer: a prospective phase II CRAB trial
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018 : GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424. doi: 10.3322/caac.21492BrayFFerlayJSoerjomataramISiegelRLTorreLAJemalA. Global cancer statistics2018GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countriesCA Cancer J Clin20186839442410.3322/caac.2149230207593Open DOISearch in Google Scholar
Zadnik V, Primic Zakelj M, Lokar K, Jarm K, Ivanus U, Zagar T. Cancer burden in Slovenia with the time trends analysis. Radiol Oncol 2017; 51: 47-55. doi: 10.1515/raon-2017-0008ZadnikVPrimic ZakeljMLokarKJarmKIvanusUZagarTCancer burden in Slovenia with the time trends analysisRadiol Oncol201751475510.1515/raon-2017-0008533017428265232Open DOISearch in Google Scholar
Ludmir EB, Palta M, Willett CG, Czito BG. Total neoadjuvant therapy for rectal cancer: An emerging option. Cancer 2017; 123: 1497-506. doi: 10.1002/cncr.30600LudmirEBPaltaMWillettCGCzitoBGTotal neoadjuvant therapy for rectal cancer: An emerging optionCancer2017123149750610.1002/cncr.3060028295220Open DOISearch in Google Scholar
Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-40. doi: 10.1056/NEJMoa040694SauerRBeckerHHohenbergerWRödelCWittekindCFietkauRet alPreoperative versus postoperative chemoradiotherapy for rectal cancerN Engl J Med200435117314010.1056/NEJMoa04069415496622Open DOISearch in Google Scholar
Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012; 30: 1926-33. doi: 10.1200/JCO.2011.40.1836SauerRLierschTMerkelSFietkauRHohenbergerWHessCet alPreoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 yearsJ Clin Oncol20123019263310.1200/JCO.2011.40.183622529255Open DOISearch in Google Scholar
Mody K, Baldeo C, Bekaii-Saab T. Antiangiogenic therapy in colorectal cancer. Cancer J 2018; 24: 165-70. doi: 10.1097/PPO.0000000000000328ModyKBaldeoCBekaii-SaabTAntiangiogenic therapy in colorectal cancerCancer J2018241657010.1097/PPO.000000000000032830119079Open DOISearch in Google Scholar
Nieder C, Wiedenmann N, Andratschke NH, Astner ST, Molls M. Radiation therapy plus angiogenesis inhibition with bevacizumab : rationale and initial experience. Rev Recent Clin Trials 2007; 2: 163-8. doi: 10.2174/157488707781662733NiederCWiedenmannNAndratschkeNHAstnerSTMollsMRadiation therapy plus angiogenesis inhibition with bevacizumab : rationale and initial experienceRev Recent Clin Trials20072163810.2174/15748870778166273318474001Open DOISearch in Google Scholar
Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005; 23: 8136-9. doi: 10.1200/JCO.2005.03.5881WillettCGBoucherYDudaDGdi TomasoEMunnLLTongRTet alSurrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patientsJ Clin Oncol2005238136910.1200/JCO.2005.03.588116258120Open DOISearch in Google Scholar
Fornaro L, Caparello C, Vivaldi C, Rotella V, Musettini G, Falcone A, et al. Bevacizumab in the pre-operative treatment of locally advanced rectal cancer : a systematic review. World J Gastroenterol 2014; 20: 6081-91. doi: 10.3748/wjg.v20.i20.6081FornaroLCaparelloCVivaldiCRotellaVMusettiniGFalconeAet alBevacizumab in the pre-operative treatment of locally advanced rectal cancer : a systematic reviewWorld J Gastroenterol20142060819110.3748/wjg.v20.i20.6081403344724876730Open DOISearch in Google Scholar
Willett CG, Duda DG, Di Tomaso E, Boucher Y, Ancukiewicz M, Sahani D V, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: multidisciplinary phase II study. J Clin Oncol 2009; 27: 3020-6. doi: 10.1200/JCO.2008.21.1771WillettCGDudaDGDiTomaso EBoucherYAncukiewiczMSahaniD Vet alEfficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: multidisciplinary phase II studyJ Clin Oncol2009273020610.1200/JCO.2008.21.1771270223419470921Open DOISearch in Google Scholar
García M, Martinez-Villacampa M, Santos C, Navarro V, Teule A, Losa F, et al. Phase II study of preoperative bevacizumab, capecitabine and radiotherapy for resectable locally-advanced rectal cancer. BMC Cancer 2015; 15: 59. doi: 10.1186/s12885-015-1052-0GarcíaMMartinez-VillacampaMSantosCNavarroVTeuleALosaFet alPhase II study of preoperative bevacizumab, capecitabine and radiotherapy for resectable locally-advanced rectal cancerBMC Cancer2015155910.1186/s12885-015-1052-0Open DOISearch in Google Scholar
Sprangers MA, Te Velde A, Aaronson NK. The construction and testing of the EORTC colorectal cancer-specific quality of life questionnaire module (QLQ-CR38). Eur J Cancer 1999; 35: 238-47. doi: 10.1016/S0959-8049(98)00357-8SprangersMATe VeldeAAaronsonNKThe construction and testing of the EORTC colorectal cancer-specific quality of life questionnaire module (QLQ-CR38)Eur J Cancer1999352384710.1016/S0959-8049(98)00357-8Open DOISearch in Google Scholar
Gujral S, Conroy T, Fleissner C, Sezer O, King PM, Avery KN, et al. Assessing quality of life in patients with colorectal cancer : an update of the EORTC quality of life questionnaire. Eur J Cancer 2007; 43: 1564-73. doi: 10.1016/j. ejca.2007.04.005GujralSConroyTFleissnerCSezerOKingPMAveryKNet alAssessing quality of life in patients with colorectal cancer : an update of the EORTC quality of life questionnaireEur J Cancer20074315647310.1016/j.ejca.2007.04.00517521904Open DOISearch in Google Scholar
Ganesh V, Agarwal A, Popovic M, Cella D, Mcdonald R, Vuong S, et al. Comparison of the FACT-C , EORTC QLQ-CR38 , and QLQ-CR29 quality of life questionnaires for patients with colorectal cancer: a literature review. Support Care Cancer 2016; 24: 3661-8. doi: 10.1007/s00520-016-3270-7GaneshVAgarwalAPopovicMCellaDMcdonaldRVuongSet alComparison of the FACT-C , EORTC QLQ-CR38 , and QLQ-CR29 quality of life questionnaires for patients with colorectal cancer: a literature reviewSupport Care Cancer2016243661810.1007/s00520-016-3270-727193118Open DOISearch in Google Scholar
Velenik V, Ocvirk J, Mušič M, Bračko M, Anderluh F, Oblak I, et al. Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study. Radiat Oncol 2011; 6: 105. doi: 10.1186/1748-717X-6-105VelenikVOcvirkJMušičMBračkoMAnderluhFOblakIet alNeoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II studyRadiat Oncol2011610510.1186/1748-717X-6-105317972021880132Open DOISearch in Google Scholar
Aaronson N, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez N, et al. The European organisation for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76. doi: 10.1093/jnci/85.5.365AaronsonNAhmedzaiSBergmanBBullingerMCullADuezNet alThe European organisation for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncologyJ Natl Cancer Inst1993853657610.1093/jnci/85.5.3658433390Open DOISearch in Google Scholar
Fayers P, Aaronson N, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLQ-C30 scoring manual. 3rd Edition. Brussels: European Organisation for Research and Treatment of Cancer; 2001.FayersPAaronsonNBjordalKGroenvoldMCurranDBottomleyAEORTC QLQ-C30 scoring manual3rd EditionBrusselsEuropean Organisation for Research and Treatment of Cancer2001Search in Google Scholar
Velenik V, Anderluh F, Oblak I, Strojan P, Zakotnik B. Capecitabine as a radio-sensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial. Croat Med J 2006; 47: 693-700. PMID: 17042060VelenikVAnderluhFOblakIStrojanPZakotnikBCapecitabine as a radio-sensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trialCroat Med J200647693700PMID: 17042060Search in Google Scholar
Gasparini G, Torino F, Ueno T, Cascinu S, Troiani T, Ballestrero A, et al. A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. Angiogenesis 2012; 15: 141-50. doi: 10.1007/s10456-011-9250-0GaspariniGTorinoFUenoTCascinuSTroianiTBallestreroAet alA phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancerAngiogenesis2012151415010.1007/s10456-011-9250-022212406Open DOISearch in Google Scholar
Couwenberg AM, Burbach JPM, van Grevenstein WMU, Smits AB, Consten ECJ, Schiphorst AHW, et al. Effect of neoadjuvant therapy and rectal surgery on health-related quality of life in patients with rectal cancer during the first 2 years after diagnosis. Clin Colorectal Cancer 2018; 17: 499-512. doi: 10.1016/j.clcc.2018.03.009CouwenbergAMBurbachJPMvan GrevensteinWMUSmitsABConstenECJSchiphorstAHWet alEffect of neoadjuvant therapy and rectal surgery on health-related quality of life in patients with rectal cancer during the first 2 years after diagnosisClin Colorectal Cancer20181749951210.1016/j.clcc.2018.03.00929678514Open DOISearch in Google Scholar
Kim NK, Ba ik SH, Seong JS, Kim H, Roh JK, Lee KY, et al. Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced - impact of postirradiated pathologic downstaging on local reccurrence and survival. Ann Surg 2006; 244: 1024-30. doi: 10.1097/01.sla.0000225360.99257.73KimNKBaik SHSeongJSKimHRohJKLeeKYet alOncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced - impact of postirradiated pathologic downstaging on local reccurrence and survivalAnn Surg200624410243010.1097/01.sla.0000225360.99257.73185662117122629Open DOISearch in Google Scholar
Hernandez JM, Clark W, Weber J, Fulp WJ, Lange L, Shibata D. The impact of pathologic nodal status on survival following neoadjuvant chemoradiation for locally advanced rectal cancer. Int J Color Dis 2014; 29: 1061-8. doi: 10.1007/s00384-014-1917-8HernandezJMClarkWWeberJFulpWJLangeLShibataDThe impact of pathologic nodal status on survival following neoadjuvant chemoradiation for locally advanced rectal cancerInt J Color Dis2014291061810.1007/s00384-014-1917-824970021Open DOISearch in Google Scholar
Berger MD, Yang D, Sunakawa Y, Zhang W, Ning Y, Matsusaka S, et al. Impact of sex, age and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012. Oncotarget 2016; 7: 53668-78. doi: 10.18632/oncotarget.10696BergerMDYangDSunakawaYZhangWNingYMatsusakaSet alImpact of sex, age and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012Oncotarget20167536687810.18632/oncotarget.10696528821327449091Open DOISearch in Google Scholar
Velenik V, Oblak I, Anderluh F. Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer. Radiat Oncol 2010; 5: 88. doi: 10.1186/1748-717x-5-88VelenikVOblakIAnderluhFLong-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancerRadiat Oncol201058810.1186/1748-717x-5-88Open DOISearch in Google Scholar
Badakhshi H, Ismail M, Boskos C, Zhao K, Kaul D. The role of concomitant radiation boost in neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Anticancer Res 2017; 37: 3201-5. doi: 10.21873/anticanres.11681BadakhshiHIsmailMBoskosCZhaoKKaulDThe role of concomitant radiation boost in neoadjuvant chemoradiotherapy for locally advanced rectal cancerAnticancer Res2017373201510.21873/anticanres.1168128551665Open DOISearch in Google Scholar
O’Hare T, McDermott R, Hannon R. Late anastomotic breakdown with bevacizumab in colorectal cancers, a case-based review. Ir J Med Sci 2018; 187: 333-6. doi: 10.1007/s11845-017-1676-yO’HareTMcDermottRHannonRLate anastomotic breakdown with bevacizumab in colorectal cancers, a case-based reviewIr J Med Sci2018187333610.1007/s11845-017-1676-y28852961Open DOISearch in Google Scholar
Borzomati D, Nappo G. Infusion of bevacizumab increases the risk of intestinal perforation: results on a series of 143 patients consecutively treated. Updat Surg 2013; 65: 121-4. doi: 10.1007/s13304-013-0207-2BorzomatiDNappoGInfusion of bevacizumab increases the risk of intestinal perforation: results on a series of 143 patients consecutively treatedUpdat Surg201365121410.1007/s13304-013-0207-223532741Open DOISearch in Google Scholar
Machida E, Miyakura Y, Takahashi J, Tamaki S, Ishikawa H, Hasegawa F, et al. Bevacizumab is associated with delayed anastomotic leak after low anterior resection with preoperative radiotherapy for rectal cancer: a case report. Surg Case Rep 2019; 5: 14. doi: 10.1186/s40792-019-0573-1MachidaEMiyakuraYTakahashiJTamakiSIshikawaHHasegawaFet alBevacizumab is associated with delayed anastomotic leak after low anterior resection with preoperative radiotherapy for rectal cancer: a case reportSurg Case Rep201951410.1186/s40792-019-0573-1635721030706233Open DOISearch in Google Scholar
Floodeen H, Hallböök O, Rutegård J, Sjödahl R, Matthiessen P. Early and late symptomatic anastomotic leakage following low anterior resection of the rectum for cancer: are they different entities? Color Dis 2013; 15: 334-40. doi: 10.1111/j.1463-1318.2012.03195.xFloodeenHHallböökORutegårdJSjödahlRMatthiessenPEarly and late symptomatic anastomotic leakage following low anterior resection of the rectum for cancer: are they different entities?Color Dis2013153344010.1111/j.1463-1318.2012.03195.x22889325Open DOISearch in Google Scholar
Hyman N, Manchester TL, Osler T, Burns B, Cataldo PA. Anastomotic leaks after intestinal anastomosis: it’s later than you think. Ann Surg 2007; 245: 254-8. doi: 10.1097/01.sla.0000225083.27182.85HymanNManchesterTLOslerTBurnsBCataldoPAAnastomotic leaks after intestinal anastomosis: it’s later than you thinkAnn Surg2007245254810.1097/01.sla.0000225083.27182.85187698717245179Open DOISearch in Google Scholar
Iwamoto M, Kawada K, Hida K, Hasegawa S, Sakai Y. Delayed anastomotic leakage following laparoscopic intersphincteric resection for lower rectal cancer: report of four cases and literature review. World J Surg Oncol 2017; 15: 143. doi: 10.1186/s12957-017-1208-2IwamotoMKawadaKHidaKHasegawaSSakaiYDelayed anastomotic leakage following laparoscopic intersphincteric resection for lower rectal cancer: report of four cases and literature reviewWorld J Surg Oncol20171514310.1186/s12957-017-1208-2554046028764707Open DOISearch in Google Scholar
Lim S, Yu CS, Kim CW, Yoon YS, Park IJ, Kim JC. Late anastomotic leakage after low anterior resection in rectal cancer patients: clinical characteristics and predisposing factors. Color Dis 2016; 18: 135-40. doi: 10.1111/codi.13300LimSYuCSKimCWYoonYSParkIJKimJCLate anastomotic leakage after low anterior resection in rectal cancer patients: clinical characteristics and predisposing factorsColor Dis2016181354010.1111/codi.1330026888300Open DOISearch in Google Scholar
Matthiessen P, Lindgren R, Hallböök O, Rutegård J, Sjödahl R, Study GRCT on DS. Symptomatic anastomotic leakage diagnosed after hospital discharge following low anterior resection for rectal cancer. Color Dis 2010; 12: 82-7. doi: 10.1111/j.1463-1318.2009.01938.xMatthiessenPLindgrenRHallböökORutegårdJSjödahlRStudy GRCT on DSSymptomatic anastomotic leakage diagnosed after hospital discharge following low anterior resection for rectal cancerColor Dis20101282710.1111/j.1463-1318.2009.01938.x19594606Open DOISearch in Google Scholar
Morks AN, Ploeg RJ, Sijbrand Hofker H, Wiggers T, Havenga K. Late anastomotic leakage in colorectal surgery : a significant problem. Color Dis 2013; 15: 271-5. doi: 10.1111/codi.12167MorksANPloegRJSijbrand HofkerHWiggersTHavengaKLate anastomotic leakage in colorectal surgery : a significant problemColor Dis201315271510.1111/codi.1216723398601Open DOISearch in Google Scholar
Shin US, Kim CW, Yu CS, Kim JC. Delayed anastomotic leakage following sphincter-preserving surgery for rectal cancer. Int J Color Dis 2010; 25: 843-9. doi: 10.1007/s00384-010-0938-1ShinUSKimCWYuCSKimJCDelayed anastomotic leakage following sphincter-preserving surgery for rectal cancerInt J Color Dis201025843910.1007/s00384-010-0938-120387070Open DOISearch in Google Scholar
Watanabe J, Ota M, Kawaguchi D, Shima H, Kaida S, Osada S, et al. Incidence and risk factors for rectovaginal fistula after low anterior resection for rectal cancer. Int J Color Dis 2015; 30: 1659-66. doi: 10.1007/s00384-015-2340-5WatanabeJOtaMKawaguchiDShimaHKaidaSOsadaSet alIncidence and risk factors for rectovaginal fistula after low anterior resection for rectal cancerInt J Color Dis20153016596610.1007/s00384-015-2340-526248793Open DOISearch in Google Scholar
Matthiessen P, Hansson L, Sjödah l, Rutegård J. Anastomotic-vaginal fistula ( AVF) after anterior resection of the rectum for cancer - occurrence and risk factors. Color Dis 2010; 12: 351-7. doi: 10.1111/j.1463-1318.2009.01798.xMatthiessenPHanssonLSjödahlRutegårdJAnastomotic-vaginal fistula ( AVF) after anterior resection of the rectum for cancer - occurrence and risk factorsColor Dis201012351710.1111/j.1463-1318.2009.01798.x19220383Open DOISearch in Google Scholar
Velenik V, Šečerov-Ermenc A, But-Hadžić J, Zadnik V. Health-related quality of life assessed by the EORTC QLQ-C30 questionnaire in the general slovenian population. Radiol Oncol 2017; 51: 342-50. doi: 10.1515/raon-2017-0021VelenikVŠečerov-ErmencABut-HadžićJZadnikVHealth-related quality of life assessed by the EORTC QLQ-C30 questionnaire in the general slovenian populationRadiol Oncol2017513425010.1515/raon-2017-0021561199928959171Open DOISearch in Google Scholar
Grosek J, Novak J, Kitek K, Bajrič A, Majdič A, Košir JA. Health-related quality of life in Slovenian patients with colorectal cancer: a single tertiary care center study. Radiol Oncol 2019; 53: 231-7. doi: 10.2478/raon-2019-0015GrosekJNovakJKitekKBajričAMajdičAKoširJAHealth-related quality of life in Slovenian patients with colorectal cancer: a single tertiary care center studyRadiol Oncol201953231710.2478/raon-2019-0015657250030893057Open DOISearch in Google Scholar
Nagpal K, Bennett N. Colorectal surgery and its impact on male sexual function. Curr Urol Rep 2013; 14: 279-84. doi: 10.1007/s11934-013-0341-xNagpalKBennettNColorectal surgery and its impact on male sexual functionCurr Urol Rep2013142798410.1007/s11934-013-0341-x23716030Open DOISearch in Google Scholar
Chew M, Yeh Y, Lim E, Seow-Choen F. Pelvic autonomic nerve preservation in radical rectal cancer surgery: changes in the past 3 decades. Gastroenterol Rep 2016; 4: 173-85. doi: 10.1093/gastro/gow023ChewMYehYLimESeow-ChoenFPelvic autonomic nerve preservation in radical rectal cancer surgery: changes in the past 3 decadesGastroenterol Rep201641738510.1093/gastro/gow023497668527478196Open DOISearch in Google Scholar
